Industry Impact Weighed As US Supreme Court Refuses Skinny-Label Review
Teva Vows To Fight On With ‘Additional Defenses’ As Case Returns To District Court
Teva has been denied in its attempt to convince the US Supreme Court to re-examine long-running litigation with GSK over skinny-label carve-outs of generic indications. However, the generics firm has vowed to fight on as the case is returned to the district court level, while the wider off-patent industry weighs the impact of the latest decision.
You may also be interested in...
Stage Set For Generics To Triumph With Skinny-Label Reversal
With the US solicitor general offering support for Teva over GSK in long-running litigation over skinny-label carve-outs of generic indications, the stage could be set for a major reversal at the Supreme Court that would favor the generics industry.
Vascepa Infringement Dismissal ‘Resulted In Multiple Errors,’ Amarin Argues
Amarin is digging deep to take Hikma back before a US district court in its induced infringement case against the generics manufacturer.
GSK Rebuts Teva’s ‘Doomsday Scenario’ On Skinny-Label Generics
GSK has lodged its opposition to Teva’s bid to resurrect long-running US litigation over “skinny-label” indication carve-outs at the Supreme Court level, claiming that Teva’s warnings of a “doomsday scenario” for generics are overstated.